title: Positron tomographic assessment of androgen receptors in prostatic carcinoma.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the feasibility of androgen receptor (AR) imaging with 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) by positron emission tomography (PET) and to assess the binding selectivity of FDHT to AR in patients with prostate cancer.
  
  
  METHODS
  Twenty men (age range 56-87 years) with advanced prostate cancer were studied. All except one had metastatic disease confirmed by biopsy and/or radiological studies. One patient who had radiological findings suggesting a single hepatic metastasis was found to have focal fatty infiltration on biopsy obtained after FDHT-PET and was excluded from further data analysis. FDHT uptake was assessed semiquantitatively by determination of the standardized uptake value (SUV) and tumor-to-muscle ratio (T/M). Additionally, to assess the AR binding selectivity of FDHT, patients with one or more foci of abnormally increased FDHT accumulation were studied after administration of an AR antagonist (flutamide).
  
  
  RESULTS
  Conventional imaging demonstrated innumerable lesions in two patients and 43 lesions in the remaining 17 patients with advanced prostate cancer. FDHT-PET was positive in 12 of 19 patients (sensitivity of 63%), including the two patients with innumerable lesions. FDHT-PET detected 24 of 28 known lesions (86%) in the remaining ten patients. In addition, FDHT-PET detected 17 unsuspected lesions in five of these ten patients. All 12 patients with positive FDHT-PET underwent a repeat PET study after receiving flutamide for 1 day (250 mg t.i.d.). In all of these patients, there was a decrease in tumor FDHT uptake after flutamide; the mean (+/- standard deviation) SUV and T/M decreased from 7.0+/-4.7 and 6.9+/-3.9, respectively, to 3.0+/-1.5 and 3.0+/-1.6, respectively (p=0.002). The mean PSA in patients with positive FDHT-PET was significantly higher than that in patients with negative FDHT-PET (p=0.006).
  
  
  CONCLUSIONS
  Our results document the feasibility of PET imaging of prostate cancer with FDHT and suggest that tumor uptake of FDHT is a receptor-mediated process. Positive PET studies were associated with higher PSA levels and thus, presumably, with greater tumor burden.
authors.affiliation: The Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, USA. dehdashtif@mir.wustl.edu
authors.forename: Farrokh
authors.initials: F
authors.lastname: Dehdashti
authors.forename: Joel
authors.initials: J
authors.lastname: Picus
authors.forename: Jeff M
authors.initials: JM
authors.lastname: Michalski
authors.forename: Carmen S
authors.initials: CS
authors.lastname: Dence
authors.forename: Barry A
authors.initials: BA
authors.lastname: Siegel
authors.forename: John A
authors.initials: JA
authors.lastname: Katzenellenbogen
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Welch
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism*; D000368:Aged; D000369:Aged, 80 and over; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005240:Feasibility Studies; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011467:Prostate / Q000000981:diagnostic imaging / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism*
chemical_list: C494901:16-fluorodihydrotestosterone; D005462:Fluorine Radioisotopes; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D017430:Prostate-Specific Antigen
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: J Nucl Med. 1995 Oct;36(10 ):1766-74
references.pmid: 7562040
references.citation: Mol Cell Endocrinol. 1999 Oct 25;156(1-2):85-93
references.pmid: 10612426
references.citation: Cancer Metastasis Rev. 2001;20(3-4):207-23
references.pmid: 12085963
references.citation: J Nucl Med. 1996 Jun;37(6):1009-15
references.pmid: 8683293
references.citation: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63
references.pmid: 10318905
references.citation: J Urol. 2002 Jul;168(1):9-12
references.pmid: 12050481
references.citation: Eur J Nucl Med. 1999 Jan;26(1):51-6
references.pmid: 9933662
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2927-41
references.pmid: 15184404
references.citation: J Biol Chem. 1993 Sep 5;268(25):19004-12
references.pmid: 8360187
references.citation: Clin Cancer Res. 1996 Jun;2(6):933-9
references.pmid: 9816253
references.citation: Endocr Relat Cancer. 1999 Dec;6(4):487-502
references.pmid: 10730903
references.citation: Urol Clin North Am. 1991 Feb;18(1):15-24
references.pmid: 1992569
references.citation: Lab Invest. 2002 Nov;82(11):1591-8
references.pmid: 12429819
references.citation: Cancer Res. 2001 May 1;61(9):3550-5
references.pmid: 11325816
references.citation: Prostate. 1998 Apr 1;35(1):63-70
references.pmid: 9537601
references.citation: J Nucl Med. 1991 Aug;32(8):1532-7
references.pmid: 1869974
references.citation: J Nucl Med. 1991 Aug;32(8):1526-31
references.pmid: 1869973
references.citation: Semin Oncol. 1999 Aug;26(4):407-21
references.pmid: 10482183
references.citation: Radiology. 1988 Oct;169(1):45-8
references.pmid: 3262228
references.citation: J Endocrinol. 1996 Oct;151(1):1-11
references.pmid: 8943763
references.citation: J Nucl Med. 1985 Jan;26(1):37-42
references.pmid: 2981300
references.citation: J Nucl Med. 2004 Mar;45(3):366-73
references.pmid: 15001675
references.citation: J Nucl Med. 1992 May;33(5):724-34
references.pmid: 1569482